Civica Rx’s Post

The FDA has just dropped three major updates that are set to reshape the clinical trial landscape. This is HUGE news for innovation at Cardiex! Key takeaways and how they impact us: Decentralized Trials (DCTs): The FDA is giving the green light to more remote, tech-driven trials. Our CONNEQT Pulse and advanced arterial health monitoring solutions are a perfect fit for this trend, offering top-notch remote monitoring capabilities. Integration into Clinical Practice: The FDA wants trials to be more integrated into everyday healthcare. Our SphygmoCor XCEL technology provides detailed arterial health insights that can be seamlessly incorporated into both trials and routine care, improving patient outcomes. Multiregional Oncology Trials: The FDA is emphasizing the importance of global reach in oncology trials. Our solutions are designed to support these efforts, ensuring accurate and consistent data collection across different populations. While these new guidelines offer exciting opportunities, at Cardiex, we're committed to providing flexible, advanced solutions that make the transition to these new trial designs as smooth as possible. #Cardiex #FDA #ClinicalTrials #DecentralizedTrials #DHT #Oncology #ArterialHealth #Biopharma #DigitalHealth #VascularHealth

Though prospective, this methodology delivers nearly real-time data and insights in large volumes.

There is tremendous value to patients and health delivery systems when a respected molecular pathologist decides to publicly champion the value of Comprehensive Genomic Profiling (CGP) in the context of modern cancer care. Patients in community hospitals are often receiving non-optimized treatments because their hospitals do not have point-of-care capability to properly diagnose the targetable drivers of their cancers. This often leads to significant delays, unnecessary toxicity, and death. CGP is finally becoming the standard of care in diagnostic oncology and Brandon Sheffield from the William Osler Health System should be congratulated for encouraging other community hospital systems to embrace the life-changing value of CGP. It has never been easier and cost-effective to incorporate molecular sequencers at the point-of-care. For example, companies like Oxford Nanopore Technologies now offer sequencers that sit in the palm of your hand and are very inexpensive to purchase and operate. If you're a foundation, please consider incorporating point-of-care sequencers at your respective care centres. If you're a patient or a caregiver, watching this video has the power to extend your life or the life of your loved-one. If you're a medical professional who works within the oncology community, this video will better inform your practice. If you're part of a governing body, this will provide insight into how implementing CGP at community hospitals saves money while also saving lives. If you're a patient advocate or a patient advocacy group, please share with your community and help celebrate this life-saving work. #PrecisionMedicine #CancerResearch #PrecisionOncology #AACR24 #genomicProfiling https://lnkd.in/ggn3XDaB Catalina Lopez-Correa, Miyo Yamashita, Barry D. Stein, University Health Network, Sunnybrook, MUHC Foundation, BC Cancer, Razelle Kurzrock, Vivek Subbiah, MD, TargetCancer Foundation, Stacey Silverberg, The Janssen Pharmaceutical Companies of Johnson & Johnson, Roche, Merck, Eli Lilly and Company, Bayer | Oncology, American Society of Clinical Oncology (ASCO), Cancer Care Ontario | Action Cancer Ontario, Ontario Institute for Cancer Research, Canadian Cancer Society, AYA CAN - Canadian Cancer Advocacy, Myeloma Canada | Myélome Canada, CCRAN, Save Your Skin Foundation, Pfizer, Amgen, bioMérieux, CADTH, Eva Villalba, M.B.A., MSc., VBHC Green Belt; Ian Stedman

In this week's #health top stories: Eli Lilly and OpenAI use AI to combat antimicrobial resistance, while digital, organ donation, and drug innovations advance healthcare accessibility. This and more in your weekly roundup! #MexicoBusinessNews #MexicoBusiness #WeeklyRoundups

Our Executive Director, James Minow, recently returned from the 2024 Global Conference on Myositis (GCOM) in Pittsburgh and was quite optimistic about the outcomes. GCOM brings together some of the brightest minds in JM research and care to share results and collaborate on future projects that will lead to improved treatments for myositis patients. The three-day event included a range of topics and innovation from pioneering doctors representing the Cure JM Clinical Care Network. Dr. Jessica Turnier, who we recently featured, presented her team’s research that aims to identify new biomarkers to predict flares and better target treatments that work for individuals. Other major highlights included the very real promise of CAR-T therapy in myositis for patients who haven’t responded to traditional treatments. In Jim’s words, “What we heard about CAR-T therapy was more than promising – it was astounding.” In Jim’s estimation the inescapable takeaway from GCOM 2024 was the idea that we have entered a new exciting era for clinical trials in juvenile myositis. Over the past year, there has been a boom of biotech startups and established pharmaceutical companies investing resources in bringing hopeful new treatments to clinical trials. The next frontier of research will likely lead to new, improved treatment options for our families. To read Jim’s full GCOM Round-Up, which is full of hope and promise, visit https://lnkd.in/duYpycFT

# Only Put Off Until Tomorrow What You Are Willing to Die Having Left Undone ## Embrace the Future of Healthcare Investing with NuCana's Results NuCana plc has recently announced exciting developments in their clinical trials for NUC-7738 and NUC-3373, showcasing promising results. In their Phase 2 trials, NUC-7738 demonstrated significant disease control when combined with pembrolizumab, as presented at the esteemed ESMO Congress 2024. This breakthrough innovation, particularly in treating melanoma, opens new possibilities for patients seeking effective treatment options. ## Seize the Opportunity and Avoid the Fear of Missing Out As an experienced and successful investment advisor, I urge you to explore the potential of investing in NuCana. By capitalizing on this positive update, you have the chance to not only contribute to advancements in healthcare but also grow your Health Savings Account \(HSA\). ## Act Now and Transform Your HSA Investment Strategy Investing in healthcare has always been a sensible choice, and with NuCana's encouraging clinical trial results, it becomes even more compelling. Don't miss out on the opportunity to be at the forefront of innovation, while securing financial growth for yourself and your family. ## Join the Movement - #HSA #Investing #Healthcare #Health #Family #Wellness 💪📈 Embrace the future, invest in your health, and secure your financial well-being. Take action today to maximize the potential of your HSA by adding NuCana to your investment portfolio. Let's collaborate to unlock the full potential of your HSA, ensuring a healthier tomorrow and a brighter financial future. #HSAINVESTING #HEALTHCAREINVESTMENT #INVESTINYOURHEALTH #FAMILYWELLNESS 🚀💰

📢 ICYMI 📢 Canopy recently announced the launch of Operator Pathways, an intelligent workflow tool to help phone operators accurately identify and escalate high-risk issues reported during patient calls. Read below to learn how Canopy is partnering with oncology care teams to redefine the standard for triage processes and continuous care management. #OncologyCare #Pathways #HealthTech #PatientFirst #TriageOptimization #Communitystrong #oncologynursing

🔍 Workforce Challenges at Clinical Trial Sites 🔍 Oncology clinical trial sites face unique workforce challenges that can impact trial efficiency and outcomes. From managing high workloads to ensuring staff retention, we want to hear from you! 💡 What are the primary workforce challenges you face at your clinical trial site? 💡What strategies are you implementing to manage these challenges effectively? Drop a comment and share your experiences and insights with our community! #ClinicalTrials #OncologyResearch #HealthcareWorkforce #ClinicalOperations #WorkforceManagement

🚨 Telesitters in Oncology and Rare Disease Clinical Trials: Game-Changer or Gamble? 🚨 Use of telesitters - or remote patient monitoring systems - had gained traction in healthcare facilities in the early 2010s. In the current rapidly evolving world of added technology use for clinical trials paired with high amount of oncology and rare disease clinical trials, competition for the same patients, limited site staff, need for greater clinical trial cost management and shorter clinical trial timelines, is telesitter use the right fit for your oncology and rare disease trials? 🤔 📽️ View the post below to see how I explore 4 potential benefits and 4 potential disadvantages of integrating telesitters into your oncology and rare disease clinical trial operations. From enhanced patient safety to operational hurdles, it’s clear this innovation isn’t without its challenges. 💡 The Question: Do telesitters add value to patient monitoring in oncology and rare disease trials, or do the risks outweigh the rewards? 🌟 Key Takeaways: How telesitters can cut costs without compromising care 💸 Potential pitfalls like data privacy concerns and technical limitations 🔐 💡 Watch now and decide for yourself 🔊 Let’s ignite a conversation! Do you think telesitters are a net positive for clinical trials? Share your thoughts below. 👇 #ChoiceClinOps #PatientCentricOncologyClinicalTrials #ClinicalTrials #OncologyClinicalTrials #RareDisease #Telesitter #PatientSafety #PharmaInnovation #ClinicalResearch #Biotech #Biopharma #DCT #RemotePatientMonitoring #CancerClinicalTrials

The Florida Alliance for Healthcare Value in partnership with Midwest Business Group on Health (MBGH) has released its #EmployerGuide and #InsightsforOncologyManagement. https://lnkd.in/gsuwT6u2 The #guide, set up as a #microsite, is the culmination of an #OncologyLearningCollaborative conducted with the employer members of both coalitions and includes information on key #strategies that #employers can adopt in partnership with their vendors to better manage #oncology care and costs, insights for managing oncology #benefits and communicating with their members and actions steps to support each key area. As a #living document, it will be updated regularly with new information.